● Founded in 1980 and based in New Jersey, Integrated BioPharma manufactures and distributes vitamins, nutritional supplements and herbal products, largely through contractManufacturingfor distributors, marketers and healthcare providers.
Infinity Pharmaceuticals, Inc (OTC:INFIQ) once carried real ambition in cancer immunotherapy, and for years its shares traded actively onNasdaqunder INFI. Today the story reads very differently. The ticker now appears as INFIQ, the letter markets attach to companies in bankruptcy, and the stock changes …
● 6% single-session rally, but on a stock priced around a nickel that equates to a fraction of a cent, and no confirmed catalyst explains that specific move.
● MiNK Therapeutics is one of the smaller, more speculative names in cell therapy, and its stock behaves accordingly, capable of sharp swings on modest volume.
● Notably, the roughly 3% decline came even as Humacyte announced positive news, underscoring that the move had no clear negative catalyst and likely reflects thin, low-priced trading rather than a fundamental shift.
A sharp intraday slide has pushed Healthy Extracts Inc back onto the radar of speculative traders, even as the small nutraceutical company reports its fastest revenue growth in years. The move in HEALTHY EXTRACTS INC (OTCQB: HYEX) shares, flagged as a sharp drop on …
● Hyperfine has spent 2026 trying to convince the market that portable, point-of-care brain imaging can become a durable commercial business, and the stock's slide back below a dollar shows how much work remains.
Momentum in the U.S. breast-cancer treatment market has become the defining theme for IceCure Medical Ltd (NASDAQ:ICCM), the Israeli developer of minimally invasive cryoablation technology.
SeaStar Medical Holding Corporation (NASDAQ:ICU) gave investors a modest reason to cheer, with its shares climbing about 5% in a recent session. The Nasdaq-listed maker of a novel kidney-injury therapy, ticker ICU, has been building a commercial track record for QUELIMMUNE, its treatment for …
● The recent decline of roughly 3% is a small move with no single verified catalyst attached to the session, consistent with theVolatilitytypical of a sub-$1 stock.